Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-No U.S. rate rise until 2024?

Fri, 30th Apr 2021 10:07

* Europe's STOXX 600 up 0.1%

* Basic materials index worst performer, down 1%

* Barclays tumbles after cautious guidance

* Healthcare stock index leads gains up 0.8%

April 30 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

NO U.S. RATE RISE UNTIL 2024? (0905 GMT)

A Fed tapering might be dangerous for equities, but we
should also ask ourselves if investors have already priced that
in.

UBS analysts have a pretty clear idea on the matter. They
expect “discussions on bond purchase tapering (by the Fed) to
surface in the second half of the year.”

But they “believe markets have largely priced in this
expectation.” In addition, they “do not expect any rate hike
until 2024.”

This would mean that equities will benefit from the
ultra-loose policy by the U.S. government, without worrying
about yields for a reasonable length of time.

But there are still reasons to expect more market turbulence
“as investors fret over rising inflation and the uneven global
progress in combating the pandemic,” UBS analysts say.

Bottom line, equities can rise further, but better to be
exposed to the “cyclical part of the market such as financials,
energy and value stocks.”

The chart shows the 10-year U.S. bond yields and the U.S.
dollar forward inflation-linked swap.

(Stefano Rebaudo)

*****

EARNINGS PROP UP STOXX, BUT BANKS UNDER PRESSURE (0745 GMT)

European stocks opened slightly higher as a batch of solid
company results boosted risk sentiment and offset worries about
rising bond yields.

The STOXX 600 index is up 0.2% with autos,
construction and materials stocks leading gains. Banks
are on the negative side, down 0.7% after yesterday’s
rise.

Barclays shares are down 5.5% after results.

Shares in AstraZeneca are rising 2.7% after the
company reports Q1 profit and sales ahead of expectations and
forecast higher sales in Q2.

Swiss Re stocks are up 4% after the company swang
to Q1 net profit, which was better than analysts expectations.

Investors will focus on today’s eurozone inflation figures
which might add more fuel to the fire of worries about rising
yields. Some analysts see upside risks, while most see a modest
decline in core numbers.

Eyes also on the U.S. core PCE Price Index with analysts
expecting a sizable jump.

(Stefano Rebaudo)

*****

EUROPE MAY OFFER STEER FOR WEEKEND CHEER (0658 GMT)

It's Europe's turn to confirm an improving global outlook,
a day after strong U.S. data and upbeat earnings lifted the S&P
500 to a record high close.

So far, so good: BNP Paribas, the euro zone's biggest listed
lender, posted a better-than-expected first-quarter profit while
Q1 profit at British bank Barclays more than doubled.

Next up is GDP data. Ahead of a euro-wide number released
later this morning, France revealed its economy grew a
stronger-than-expected 0.4% in Q1, having shrunk 1.4% in the
final quarter of 2020.

The euro zone economy is forecast to have shrunk 2% in the
first quarter year-on-year, versus a 4.9% fall in the final
quarter of last year.

A flash inflation estimate is also due; economists forecast
a 1.6% rise in the headline number in April versus a 1.3%
increase in March.

These figures may seem underwhelming compared to the United
States, which grew at a 6.4% annualized rate last quarter. Yet
sentiment appears to have turned a corner thanks to a pick-up in
the COVID vaccination rollout and signs economic activity has
held up relatively well in the face of ongoing restrictions.

That view perhaps is why Germany's 10-year Bund yield is
ending April almost 10 basis points higher -- even
as the U.S. equivalent is down 10 bps.

The recovery expectations, alongside upbeat earnings have
underpinned stocks, although Asian shares slipped on Friday and
European stock futures were a touch lower.

Copper, the other key growth barometer, also slipped after a
blistering rally to $10,000 a tonne, though it is on track for
the 12th monthly gain in the past 13 months.

Finally, the U.S. dollar skidded toward a fourth straight
weekly decline against a basket of peers, undermined by the
Federal Reserve's message of ultra-low rates for longer.

Key developments that should provide more direction to
markets on Friday:

- Earnings calendar: Exxon Mobil, Chevron, AbbVie, Charter
Communications, AstraZeneca.

-Nestle has bought the brands of vitamin and supplements
maker The Bountiful Company for $5.75 billion

-Darktrace lists in London but valuation well below reported
target

- U.S. March personal spending and income numbers due out.

- Credit Suisse board member Gottschling to exit after
Greensill, Archegos losses

- China official manufacturing PMI fell to 51.1 in April.

-British house prices posted the biggest single-month
increase since 2004

- Retailer Amazon posted record Q1 profits.

(Dhara Ranasinghe)

*****

EUROPE SUBDUED ON YIELDS RISE, CHINA WORRIES (0528 GMT)

European stock futures are slightly lower with no clear
trend emerging yet as a rise in yields is expected to put
pressure on some equity sectors while a mixed picture on Asian
markets dampens risk sentiment.

China stocks lost ground overnight after weak data on
concerns about a monetary policy tightening coupled with
Sino-U.S. tensions. U.S. President Joe Biden took aim at China
in his first speech to Congress, pledging to maintain a strong
U.S. military presence Indo-Pacific.

Biden's new spending plan and the dovish stance by the Fed
continue to support risk-appetite along with U.S. data released
yesterday, which showed American economic growth accelerated in
the first quarter.

(Stefano Rebaudo)

*****

More News
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 06:30

Sanofi Q1 profit slips on generic competition, forex effects

April 25 (Reuters) - Sanofi's said on Thursday first-quarter operating income declined 14.7% as unfavourable currency effects and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.